Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
This article was originally published in Scrip
Executive Summary
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
You may also be interested in...
Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Transforming Patient Engagement At Novartis
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.